Uterine Myomas Clinical Trial
Official title:
Use of Vasopressin Versus Epinephrine to Reduce Hemorrhage During Myomectomy: a Randomized Controlled Trial
Uterine myomas (fibroids or leiomyomas) are the most common benign tumor of the female
genital tract and the leading indication for hysterectomy. Although hysterectomy is the
definitive treatment of myomas, myomectomy remains the gold standard treatment for women
desiring future fertility and uterine conservation3. However, bleeding is often a problem in
myomectomy and can results in intraoperative hypovolemic shock, postoperative anemia, pelvic
infection, and adhesions with infertility.
A number of interventions have been introduced to reduce hemorrhage during myomectomy. Two
categories of interventions can be identified: (a) Vascular interventions on uterine and/or
ovarian arteries such as artery clamping, tying, or embolization; (b) pharmacologic
interventions such as vasopressin, epinephrine, oxytocin, ergometrine, misoprostol,
sulprostone, and gonadotropin-releasing hormone (GnRH) agonist4-11. Of these, intraoperative
local injection of vasopressin causing vasospasm is most commonly used. However, there is
not a wide consensus on the use of this agent because of serious side effects reported in
literature. In addition, in several countries, including France and Italy, vasopressin has
not been commercialized because of its potential adverse effects on cardiovascular system.
Epinephrine also induces a vasoconstrictive effect on tissue that lasts longer than that of
vasopressin (5-6 hours versus 7-35 minutes) and is used during various gynecological
surgeries, endoscopic resection, and dermatologic procedures to reduce blood loss. However,
there are a few studies for the use of epinephrine to reduce hemorrhage during myomectomy.
Furthermore, a randomized comparison of epinephrine and vasopressin as hemostatic agents
during myomectomy has never been conducted. To test the hypothesis that the injections of
epinephrine and vasopressin during myomectomy are equivalent in reducing blood loss, the
investigators performed this randomized controlled study.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01048931 -
Single-port Access Laparoscopic-assisted Vaginal Hysterectomy
|
Phase 3 | |
Completed |
NCT00755755 -
PGL4001 Versus Placebo in Uterine Myomas
|
Phase 3 | |
Terminated |
NCT01858454 -
Hand-assisted Laparoscopic Surgery (HALS) for Myomectomy
|
Phase 3 | |
Completed |
NCT00874029 -
Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids
|
N/A | |
Completed |
NCT00743080 -
Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators
|
Phase 4 | |
Recruiting |
NCT04400942 -
Predictive Factors for Complete Myoma Resection During Hysteroscopic Myomectomy
|
||
Completed |
NCT01745432 -
Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery
|
Phase 1 | |
Completed |
NCT00740831 -
PGL4001 Versus GnRH-agonist in Uterine Myomas
|
Phase 3 |